EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... October 11, 2019 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Reflecting On My Time As the Cancer.Net Editor in Chief May 26, 2021 The new home for your research tools April 11, 2022 Load more HOT NEWS ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... A New Study Suggests Screen Time Might Not Be The Worst... EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan ESMO Open: First Official Impact Factor of 5.329
